

## Index

### **a**

- accessory plasmid (AP) 94, 95
- acetylcholinesterase (AChE) inhibitors 65
- para*-acetyl-phenylalanine 218, 219
- activation-induced cytidine deaminase (AID) 18, 328
- active learning 146, 147
- active machine learning 147
- active pharmaceutical ingredients (API) preparation 283
  - atorvastatin 267
  - boceprevir 276
  - (*S*)-clopidogrel 279
  - esomeprazole 273, 274
  - islatravir 281, 282
  - solifenacin 275
  - ticagrelor 268
  - vibegron 270
- advanced pattern recognition 141
- Agilent RapidFire system 63
- aglycosylated IgG1 Fcs 334
- AHLR MT1-MMP biosensor 390, 391
- alkaline ligninases 308
- amine oxidases (AOs) 274–276
- amino acid bias 118, 119
- amino acid dehydrogenases (AADHs) 271–272
- aminoacyl-tRNA synthetases (AARSs) 12, 95, 246, 247
- para*-amino-phenylalanine 218, 219
- amitriptyline 226
- ammonia lyases 278
- AND-gated CARs 358
- antibiotic resistance markers 95
- antibodies 383–384
  - bispecific 320–321
  - half-life extension 330
  - half-life reduction 331
  - host-derived 325
  - manufacturability of 336–337
  - and protein scaffolds 383, 384
  - single domain 321
  - synthetic library derived 324–325
  - target-binding 324
  - therapeutic optimization of 328–336
  - yield improvement strategies
    - codon usage 337
    - expression optimization 338
    - signal peptide optimization 337
- antibody-dependent cellular cytotoxicity (ADCC) 331, 332
- antibody-dependent cellular phagocytosis (ADCP) 331
- antibody-drug conjugates (ADCs) 317, 319–320
- antibody formats 318, 319
  - antibody-drug conjugates (ADCs) 319–320
  - bispecific antibodies 320–321
  - chimeric antigen receptors 321–322
  - human IgG1 structure 318–319
  - single domain antibodies 321
- antibody-like protein scaffolds 384
- antibody-mediated therapeutic effects 332

- antibody-receptor interactions 329
- antibody target identification 322–323
- antibody therapeutics 317, 318, 323, 337
- antigen-recognition domain
- engineering CARs 360
  - enhancing CAR modularity 359
  - smarter CARs 356–359
  - single-chain variable fragment 356
  - tuning for toxicity management 356
- anti-HER2 CARs 356, 365, 366
- anti-Markovnikov oxidation 217
- arginine-specific biosensor (LysG) 38
- artemisinin 220, 221, 228, 229
- artificial metalloenzyme
- carbene formation and insertion 192
  - chemoenzymatic optimization of 195
  - Diels–Alder reaction 187–188
  - evolution protocol 194
  - for hydroquinone amine oxidation 178–179
  - for nitrite reduction 179
  - oxygen reduction reaction (ORR) 180
  - for phenol oxidation 178
  - streptavidin-based 198
  - structure 193
  - sulfite reduction 181
  - transfer hydrogenation reactions 196
  - with zinc and mercury cofactors 179
- artificial osmium peroxygenase 190
- aryl-alcohol oxidase (AAO) 296
- astemizole 225
- atorvastatin 160, 267, 268, 283, 284
- autoimmune disease targets 323
- autotransporter proteins 83, 84
- avidity 332, 384
- N*<sup>ε</sup>-2-azidoethyloxycarbonyl-L-lysine 256
- b**
- Bacillus thuringiensis* toxin (Bt toxin) 96
- bacterial cell display 82
- bacterial P450 systems 210
- drug metabolites, synthesis of 224–227
  - natural products, late-stage functionalization of 220–224
  - oxyfunctionalization of small organic substrates 211–220
- Baeyer–Villiger monooxygenases (BVMOs) 273–274
- basidiomycete white-rot fungi 295
- BBz CAR-T cells 362, 363, 365
- benzophenone–alanine 255
- N*-benzyl-pyrrolidine 215, 217, 227, 228
- betaxanthin 41
- B-factor iterative test (B-FIT) 161
- biocatalysis 30, 38, 40, 105, 106, 121, 168, 186, 207–232, 248, 265
- biocontainment 256
- biological data, growth of 137
- biopanning 86
- bioremediation, of 1,2,3-trichloropropane (TCP) 280
- biosensors 29, 386
- applications 30
  - characteristics of 44–45
  - functional components 30
  - history of 30
- biotin–avidin technology 194
- biotin–streptavidin technology 192, 194–197
- biotransducer 30, 37
- bipyridylalanine (BpyAla) 254, 257, 258
- bispecific antibodies 317–321, 333, 335
- bispecific CD19/CD20 CAR 357
- BiTE<sup>®</sup> 319, 320
- blue fluorescent proteins (BFPs) 380
- BM3-star 272
- boceprevir 276, 285
- Bordetella pertussis* 323
- 1,4-butanediol 217
- c**
- caffeine demethylase activity 35
- calcium signaling 387
- cancer cell lines 391
- cancer therapies 320, 323
- carbene formation 192
- carbene insertion 191–193

- carbon dioxide reduction 186–187
- CASTER computer aid 106, 118
- CAST/ISM 106–108, 112, 116–118, 120–124
- CAR-T cell function 354–355
- CAR-T cell therapy 353
- catalytically self-sufficient P450 209, 210, 232
- cell biology applications 386
- cell signaling 387–390
  - diagnostics and medicine 390–393
  - localization 386–387
- cell culture technology 336–337
- cellobiohydrolase class II (CBHII) 145
- cellobiose 2-epimerase 278, 285
- cell-surface display techniques 93
- bacterial display systems 83–84
  - deep mutational scanning 94
  - mammalian display 85
  - modifications of 89
  - multiple proteins of 91–92
  - next-generation sequencing (NGS) techniques 94
  - phage-assisted continuous evolution (PACE) 94–96
  - phage display 81–83
  - μSCALE technique 93
  - specifications 83
  - yeast surface display (YSD) technique 84–85
- cellulosomes 92,
- β-cembrenediol, late-stage oxidation of 220
- CFP/YFP FRET-based histone methylation 389–390
- chemical mutagenesis 246
- chemoenzymatic mono- and difluorination of ibuprofen methylester 213
- C–H functionalization 180, 191
- C–H hydroxylation, using manganese porphycene 182–183
- chimeragenesis strategy 231
- chimeric antigen receptors (CARs) 319, 321
- antigen-recognition domain 356–360
  - CAR-T cell function 354–355
  - description 353
  - extracellular spacer 360–362
  - high-throughput CAR engineering 366–367
  - novel receptor modalities 367–369
  - signaling domain 362–366
  - soluble ligands, respond to 360
  - structure of 355
  - transmembrane domain 362
- C–H insertion 183, 190
- chiral acyloins, biocatalytic synthesis of 215
- chirality 255, 256
- chlorin e6 (Ce6) 182
- chronic myeloid leukemia (CML) cell resistance 19, 393
- circularly permuted fluorescent proteins (cpFPs) 383
- cis-4-proline hydroxylase 276
- class I P450s 209, 210, 215, 223, 224, 229, 230
- class II P450 systems 209, 210
- CLIP-tag 385
- C–N heteropolymeric dyes 308
- Codexis 267–269, 271, 273, 275, 276
- codon usage 301–302, 337, 380
- cofactor replacement, in native proteins 181–184, 189–192
- combinatorial active-site saturation test (CAST) 106, 161, 278
- combinatorial CD28 and 4-1BB co-stimulation 363
- Combinational Libraries Enhanced by Recombination in Yeast (CLERY) 304
- combinatorial saturation mutagenesis (CSM) 106
- compactin 224
- complementarity determining regions (CDRs) 318
- Compound (I) 207

- computationally-guided combinatorial site-saturation mutagenesis strategy 212  
 consensus design 160, 305, 306  
 consensus mutations 96, 306  
 constraint network analysis (CNA) 154, 158–159  
 counter-selection screening strategy 88  
 covalent anchoring 184–187, 192–194  
 [Cp<sup>\*</sup>RhCl<sub>2</sub>]<sub>2</sub> catalyzed aromatic C–H activation 197  
 CRISPR-guided AID strategies 19  
 CRISPRx 9, 19  
 cross-linked enzyme crystals (CLECs) 187  
 CrossMAB technology 321  
 cross-validation 142, 143  
 cyclohexanone monooxygenase (CHMO) 273  
 cyclohexylamine oxidase (CHAO) 275  
 cyclopropanation 184, 187, 192  
   C–H insertion using heme and cobalt porphyrin 183–184  
   iron–chlorin e6 cofactor 182  
   iron porphycene 182  
 CYP106A2 variants 223  
 cytochrome *c* peroxidase (CcP) 181  
 cytochrome P450 248, 251  
   biocatalysis 208  
   catalytic cycle 207, 208  
   characteristic spectral feature 207  
   degree of conformational flexibility 209  
   description 207  
   heme cofactor 209  
   in humans 207  
   improved thermostability and solubility 230–231  
   monooxygenases 272–273
- d**
- D-aminopimelic acid 271  
 data-driven approach 147, 148  
 data revolution, in biology 136–138  
 D-DNA polymerase 256  
 deep mutational scanning experiments 137, 138  
 deep mutational scanning strategy 94  
 deracemization strategy 274  
 dexamethasone (Dex) 40  
 diabodies 384  
 Diels–Alder reaction 187–188  
 dihydrofolate reductase (DHFR) 21, 40, 386  
 directed evolution 177  
   approach 3, 33, 34, 211, 265  
   Ir(Me)-mOCR-Myo mutants 190  
   process 384  
 directed evolution of metalloenzymes using *de novo* designed scaffolds 188–189  
   using native scaffolds 189–200  
 directed protein evolution 29, 105  
   biosensors characteristics of 44–45  
   *in vivo* biosensors for 57  
   nucleic acid-based *in vivo* biosensors for 32–36  
   protein-based *in vivo* biosensors for 37–43  
 dirhodium artificial metalloenzymes 192  
 DNA library 119, 120  
 DNA-puzzle 304  
 DNA-type biosensors 35–36  
 domain engineering strategy 212  
 drug-metabolizing P450<sub>BM3</sub> variant 225  
 DuBois-type catalyst 184, 185  
 Due Ferri (DF) 178  
 Dyax Fab phage libraries 324
- e**
- effector functions  
   autoimmune disease treatment 334  
   for cancer therapeutics 332–333  
   half-life modification effect 331  
   IgG1 Fc 334–335  
   for infectious disease prophylaxis and therapy 333  
 electronic paramagnetic resonance (EPR) spectroscopy 249

- engineered P450 variants  
   allylic hydroxylation of cyclopentene derivative 215  
   biocatalytic synthesis of chiral acyloins 215  
   cyclohexadiene compound  
     stereoselective hydroxylation of 215  
   hydroxylation of C<sub>8</sub>-C<sub>12</sub> cycloalkanes 213  
   1-indanone, benzylic hydroxylation of 214  
   limonene, epoxidation of 213  
   semi-rational protein engineering strategy 214  
   stereoselective hydroxylation of cyclopentene compound 215  
   1-tetralones, benzylic hydroxylation of 213–214  
   1-thiochroman-4-one, asymmetric sulfoxidation of 215
- engineered P450<sub>BM3</sub> variants  
   artemisinin, hydroxylation of 220  
   β-cembrene diol, late-stage oxidation of 220  
   for cholesterol-lowering drugs 226  
   drug lidocaine, oxidative cyclization of 218  
   drug metabolite synthesis 226  
   nigelladine A synthesis 224  
   nonsteroidal anti-inflammatory drug (NSAID) 212, 225  
   oxyfunctionalization of non-native substrates 211–220  
   parthenolide, hydroxylation of 220  
   for selective oxidation of alkanes 211, 212  
   testosterone, regio- and stereoselective oxidation of 223
- engineered P450cam variants 215  
 enzymatic ester hydrolysis 179  
 enzymatic functionalization of C–H bonds 180  
 enzymatic labeling 386  
 enzymatic process, for atorvastatin intermediates 267  
 enzyme-based technologies 105  
 enzyme engineering approach, for API preparation 283  
 enzymes in organic synthesis 265  
 enzyme-type biosensors 41–45  
 error-prone polymerase chain reaction (epPCR) 67, 105, 106, 169, 385  
*Escherichia coli*  
   targeted mutagenesis in 13–16  
   whole-cell construction 112–115  
 esomeprazole synthesis 274  
 esterases 279  
 eukaryotic rAPOBEC1 protein 42  
 EVmutation 144  
 EvolvR 7, 14–16  
 5-*exo*-hydroxycamphor 215, 229  
 exploratory NNK-based SM 111, 112, 113, 115  
 expressed protein ligation (EPL) method 246, 252  
 extracellular spacer 353, 355, 360–362  
*ex vivo* diversification, on genes of interest 3
- f**  
 Fabs 384  
 fatty acid hydroxylase P450<sub>BM3</sub> 209  
 Fc-dependent antibody effects 332  
 Fc-independent antibody effects 332  
 ferric hydroperoxy intermediate 207  
 first-generation CARs 362, 363  
 fluorescence-activated cell sorting (FACS) 13, 83, 366, 385  
 fluorescence microscopy 250, 379, 380, 386, 393, 394  
 fluorescent-activated cell sorting (FACS) 86–87  
 fluorescent proteins (FPs) 45, 379, 386  
   circularly permuted 383  
   color palette 380–381  
   photocontrollable 381–383  
   split 383  
 fluorination of aromatic residues 248

- focal adhesion kinase (FAK), subcellular localization of 389
- focused mutagenesis strategies 385
- FoldX 154–158, 171
- fragment antigen-binding (Fab) domain 384
- fragment crystallizable (Fc) domain 384
- framework for rapid enzyme stabilization by computational libraries (FRESCO) method 154–157, 171
- FRET-based biosensors 388–390
- FRET-based Ca<sup>2+</sup> biosensors 388
- FRET-based epigenetic biosensors 390
- frontal affinity chromatography (FAC)-MS 63
- fungal mineralization, of lignin 295
- FusionRed 381, 388
- fusion tags 379, 380
- g**
- Gaussian processes (GP) 144
- GCaMP 383, 387, 388
- Generalized Extracellular Molecule Sensor (GEMS) 369
- receptor platform 368
- genetically encoded calcium indicators (GECI) 387
- genetically encoded non-fluorescent protein tags 385–386
- GFP11 383, 386
- glmS* ribozyme 31–34
- glucocorticoid receptor (GR) 40
- glucose dehydrogenase (GDH) 267
- β-glucosidase point mutants 140
- glycoengineering, of N297-linked carbohydrate 335
- glycosylation 85, 282, 298, 330, 332, 334, 335, 337, 338, 385
- glyoxal oxidase (GLX) 253, 296
- h**
- haloacid dehalogenase-like phosphatases (HAD phosphatase) 34
- haloalkane dehalogenase enzymes 279
- halohydrin dehydrogenase (HHDH) 268
- HaloTag 385
- heme 112, 114, 180–184, 187–189, 191, 207, 209–213, 229, 230, 253, 295, 296, 301, 303, 305, 307
- heme–nonheme heterobimetallic system 180
- high-affinity protein-binders 12
- high-redox potential laccases (HRPLs) 299
- high-throughput CAR engineering 366–367
- high-throughput cell screening techniques 86
- fluorescent-activated cell sorting (FACS) 86–87
- magnetic-activated cell sorting (MACS) 87
- magnetic-assisted cell sorting (MACS) 87–88
- solid phase panning 86
- high-throughput next generation sequencing 327
- high-throughput screening (HTS) assays, for ligninase evolution 306–309
- of engineered P450s 227–229
- histidine 40 271
- horseradish peroxidase (HRP) variants 89, 197, 282
- Hoveyda–Grubbs catalyst 199
- HuCal Fab phage libraries 325
- human drug metabolites (HDMs) 303
- human IgG1 Fc 328–330
- human IgG1 monoclonal antibody 319
- human IgG1 structure 318–319
- human liver P450s 210, 225, 231
- hyaluronan synthases (HASs) 169
- hybrid P450 systems 229–230
- hydroformylation 185–186, 189–191
- hydrogenation 189–191, 194–197, 266
- hydrogen evolution 184
- hydroquinone amine oxidation 178–179
- hydroxycoumarin-containing UAA 250

- hydroxylated tetralone compounds 272
- 3-hydroxypropionic acid (3-HP) 31, 37, 38
- 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ -HSD) 39
- 4-hydroxy tetralone derivatives 272
- i**
- (*S*)-ibuprofen methylester 252
- ice nucleation proteins (INPs) 82, 84
- imatinib 19, 393
- imidazolidin-4-ones 218, 219
- imine reductases (IREDs) 195, 196, 276–277, 287
- immobilized enzyme reactor (IMER)-MS 63
- immunization 321–323, 325–328, 338
- immunogenicity 335–336
- reducing aggregation 336
- reducing T-cell recognition 336
- immunological synapse (IS) quality 355
- indomethacin 180
- inducible T-cell co-stimulator (ICOS) 364
- infectious disease targets 323–324
- in-house Code Evolver platform 268
- innovative sequence activity relationship (iSAR) model 160
- intermediate sensor-assisted push–pull strategy (InterSPPS) 40
- inverted receptors 367, 368
- in vitro* CRISPR/Cas9-mediated mutagenic (ICM) system 118
- in vitro* Staggered Extension Process (StEP) 304
- in vitro* stress test 354
- in vivo* DNA biosensing elements 35
- in vivo* continuous evolution
- challenges 5–9
- ep Pol I/ColE1 system 15
- OrthoRep 20–22
- PACE 10–13
- somatic hypermutation 18–20
- targeted mutagenesis, in *E. coli* 13–16
- yeast systems 16–18
- In Vivo* Overlap Extension (IVOE) protocol 302, 303
- in vivo* shuffling 300, 303, 304, 306
- Ir-based artificial transfer hydrogenase 197
- Ir(Me)-PXI CYP119 mutants 191
- iron–porphycene 182, 183
- islatravir synthesis 281, 282, 286
- ISM-based directed evolution
- amino acid alphabets selection 109–117
- methodology developments of CAST/ISM 117–120
- isomerases 278–279
- isotopic labeling 68
- iterative saturation mutagenesis (ISM) 105–124, 154, 161, 214, 215, 217, 275
- k**
- Kernel methods 143, 144
- $\alpha$ -ketoglutaric semi-aldehyde dehydrogenase (KGSADH) enzyme 37
- ketoreductase catalysed reduction
- of prochiral ketone 268
- of tetrahydrothiophene-3-one 270
- ketoreductases (KRED) 122, 267–271, 285, 287
- kinase biosensors
- drug effectiveness 392–393
- drug resistance 393
- knowledge-based directed evolution
- ISM technique 161
- KnowVolution 162–170
- MORPHING 161–162
- KnowVolution
- of aryl sulfotransferase 168–169
- computer-assisted structural analysis 164
- directed evolution round 162
- of fungal laccases 164
- of hyaluronic acid synthase 169–170
- of phytase from *Yersinia mollaretii* 169

KnowVolution (*contd.*)

- of polypropylene and polystyrene
  - binding peptides 170
- recombination 164
- site-saturation mutagenesis 163
- of sortase A 168

**L**

- lactulose 278
- LanYFP tetramer 381
- (*S*)-licarbazine 268, 269
- lidocaine 218, 226
- lignin
  - deconstruction by bacterial attack
    - 295
  - fungal mineralization 295
- ligninase evolution
  - computational strategy 306
  - high-throughput screening (HTS)
    - assays for 306–309
- ligninases 295, 297, 300–303, 306–309
- ligninolytic consortium 296, 297
- ligninolytic oxidoreductases 295
- lignin peroxidases (LiPs) 295, 296
- lignocellulose 295, 297, 309
- limonene epoxide hydrolase, catalyzed
  - hydrolytic desymmetrization
    - 109–110
- linear regression model 140–142, 145, 146
- LmrR-heme assembly 188
- localization-based super-resolution
  - microscopy 387
- logic-gated CARs 357
- logistic regression 143
- lovastatin 226, 227
- L-phenylalanines 278
- Lpp-OmpA 84
- lyases 278
- lysine-specific demethylase-1 (LSD1)
  - inhibitor 276

**m**

- machine learning 87, 136, 138, 141, 143, 147, 148, 154, 156, 159, 160, 171, 305
- machine learning-guided directed
  - evolution 160
- magnetic-activated cell sorting (MACS)
  - 87
- magnetic-assisted cell sorting (MACS)
  - 87
- MALDI MS method 59, 67, 68
- mammalian antibody display libraries
  - 338
- mammalian cell display 81, 82, 85
- mammalian cytochrome P450<sup>2F1</sup> 231
- manganese peroxidases (MnPs) 295, 296
- manganese porphycene (MnPc) 183
- mass spectrometry (MS)-based protein
  - assays
    - applications of
      - protein analysis 64–66
      - protein engineering 66–68
    - ion sources and mass analyzers 61
    - procedures and instrumentation
      - 59–62
    - robotic automation 63
    - technology advances 62–63
- mClover series 381
- MedImmune 330, 338
- megaprimer-based approach 118
- membrane-bound eukaryotic P450s 231
- membrane-type 1 matrix
  - metalloproteinase (MT1-MMP)
    - 390
- metalloproteinases (MMPs) 390
- metalloproteins 177, 245, 249, 251
- methotrexate (Mtx) 31, 40
- 3-methylaspartate ammonia lyase (MAL)
  - 278, 283
- 3-methylhistidine (3-MeHis) 251, 253
- 2-methyltetrahydroquinoline (2-MTHQ)
  - 275
- microbial phytases 169



- microcapillary single-cell analysis and
    - laser extraction ( $\mu$ SCALE) 88, 93–94
  - microfluidics-MS 62, 64, 66
  - miniaturized protein assays 62
  - minibodies 384
  - mNeonGreen 381, 383
  - Moderna 338
  - modified YSD technique 85, 89, 90
  - molecular dynamics (MD) simulations
    - 106, 135, 155, 254, 303
  - Modular Extracellular Sensor
    - Architecture (MESA) receptor 368
  - monoamine oxidase from *Aspergillus niger* (MAO-N) variants 274, 276
  - monobody 96, 379, 384, 389
  - monoclonal antibodies 317–320, 324
  - mPlum 18
  - mRuby 381
  - mScarlet 381
  - mTurquoise2 381
  - multi-enzyme cascade 281–282
  - mutability landscaping
    - exploratory NNK-based SM 115
    - of P450-BM3 116
  - mutagenesis plasmid (MP) 43, 94, 95
  - Mutagenic Organized Recombination
    - Process by Homologous *IN vivo* Grouping (MORPHING) 154, 161–162, 171, 302, 303
  - mutator plasmid (MP) 10, 11
- n**
- N*-acetyl glucosamine (GlcNAc) 33
  - N*-acetyl neuraminic acid
    - (Neu5Ac)-specific aptamer 34
  - noncanonical amino acids (ncAA) (ncAA) 95
  - nanobody formats 321
  - nanostructure-initiator mass
    - spectrometry (NIMS) 65
  - 1-naphthol synthesis 308
  - native chemical ligation methods 246
  - native proteins
    - cofactor replacement
      - directed evolution of metalloenzymes 189
      - rational design of metalloenzymes 181
    - covalent anchoring
      - directed evolution strategy 192
      - rational design of metalloenzymes 184
    - non-covalent anchoring 194–200
    - supramolecular anchoring 187–188
  - natural P450 systems 209
  - negative indicators, of CAR-T cell
    - function 355
  - negative selection strategy 89
  - neonatal Fc receptor (FcRn) 328
  - neutral genetic drift 304
  - next generation sequencing (NGS)
    - techniques 94, 327, 328
  - nickel catalyst
    - carbon dioxide reduction using 186–187
    - hydrogen evolution using 184
  - nickel-diphosphine catalysts 184
  - nicotinamide cofactors 189
  - nigelladine A synthesis 224
  - nitric oxide reductase (NOR) 180
  - nitrite reduction 179, 253
  - non-antibody binders 84
  - non-canonical P450-catalyzed reactions 217
  - non-covalent anchoring, in native
    - proteins 194–200
  - nuclear magnetic resonance (NMR)
    - spectroscopy 168, 249
  - nucleic acid-based *in vivo* biosensors
    - DNA-type biosensors 35–36
    - RNA-type biosensors 32–35
- o**
- obinutuzumab 332
  - ocaratuzumab 332
  - octanol 215, 217
  - olefin metathesis 186, 197, 199
  - OR-gate CARs 357, 359, 361

- organic solvents 105, 231, 246, 248, 265, 301, 307
- organophosphorus hydrolase (OPH) 91
- organophosphorus pesticides 91
- orthogonal DNA replication (OrthoRep) 6, 9, 20–22
- osmium–cupin complex 190, 191
- overactive bladder syndrome (OAB) 270
- OX40 co-stimulatory domain 364
- oxidoreductases
  - amine oxidases 274–276
  - amino acid dehydrogenases 271–272
  - Baeyer–Villiger monooxygenases 273–274
  - cytochrome P450 monooxygenases 272–273
  - hydroxylases 276
  - imine reductases 276–277
  - ketoreductases 267–271
- oxygen reduction reaction (ORR) activity 180
  
- p**
- P450-BM3 catalyzed C16-selective hydroxylation, of testosterone 115
- P450-catalyzed monooxygenation reactions 208
- P450 fingerprinting method 227
- P450pyr variant
  - for  $\beta$ -hydroxylation of *N*-benzyl-pyrrolidine 215
  - for octanol conversion 215
  - for propylbenzene conversion 215
- PAmCherry 382, 387
- PAmKate 382
- parthenolide 220, 221, 229
- PATagRFP 382
- pentamethylcyclopentadienyl Rh catalyst 197
- peptide-conjugated antibodies 335
- Pericam 383, 388
- peroxidation 189
  - using osmium–cupin complex 191–192
- phage-assisted continuous evolution (PACE) systems 6, 10–13, 42, 94–96
- phage-display synthetic antibody library 82
- phage-display technique 81
- phage surface display 82, 385
- phenylacetylene polymerization 186
- phenol oxidation 178
- phenol-specific transcription factors 37, 38
- 2-phenylpropionic acid, lipase-catalyzed stereoselective esterification of 67
- photoactivatable fluorescent proteins (PAFPs) 382
- photo-activation localization microscopy (PALM) 387
- photocontrollable fluorescent proteins 381–383
- photoconvertible fluorescent proteins (PCFPs) 382, 387
- photon-induced electron transfer 255
- photosensitizer protein (PSP) 255
- plant-based antibody expression 338
- Plasmodium falciparum* DHFR (*Pf*DHFR) resistance 21
- positive selection strategy 89
- post-translational modifications (PTMs) 64, 83–85, 258, 298, 338, 385, 389
- Precambrian enzyme 306
- principal component analysis (PCA) 62, 144
- Probody<sup>TM</sup> 335
- prokaryotic P450<sub>BM3</sub> 209
- proline hydroxylases 276
- propane-hydroxylating biocatalyst 212
- propane monooxygenase (P450<sub>PMO</sub>) 212
- propylbenzene 217
- propylbenzene 215, 217
- ProtaBank 136, 148
- protein-based *in vivo* biosensors
  - enzyme-type biosensors 41–43
  - transcription factor-type biosensors 37–41

- protein engineering
- cellular imaging tools development
    - antibodies and protein scaffolds 383
    - fluorescent proteins 380–381
    - genetically encoded non-fluorescent protein tags 385–386
    - photocontrollable fluorescent proteins 381–383
  - computer-aided rational design
    - CNA 158–159
    - FoldX 157–158
    - FRESCO 155–157
    - ProSAR 160–161
    - PROSS 159–160
  - protein phosphorylation 249, 389
  - protein repair one-stop shop (PROSS)
    - method 154, 159–160
  - protein's amino acid sequence 138
  - protein sequence activity relationship (ProSAR) method 146, 160–161, 269
  - protein sequence-structure-function mapping 136, 147
  - protein structures 135, 136, 139, 140, 145, 146, 154, 155, 157–159, 161, 303
  - protoporphyrin IX (ppIX) 182, 183, 207
- q**
- quantitative structure-activity relationship (QSAR) models 141, 160
  - quantum dot (QD)-FRET nanosensor 391, 392
  - quick quality control (QQC) 108
  - Q-values 109
- r**
- ratiometric FRET biosensors 388
  - rational design of metalloenzymes
    - using *de novo* designed scaffolds 177–179
    - using native scaffolds 179–188
  - receptor binding sites, on human IgG1 Fc 323, 330, 335
  - red fluorescent proteins (RFPs) 18, 379, 381, 383
  - regression methods 141, 143
  - resveratrol-responsive TtgR biosensor 39
  - retroelement-mediated mutagenesis 18
  - reversibly photoswitching fluorescent proteins (rsFPs) 382
  - rhodium catalyst
    - hydroformylation using 185–186
    - phenylacetylene polymerization using 186
  - ribonucleotide reductase (RNR) 249
  - ribosome display 334, 385
  - RNA-based *in vivo* biosensors 33
  - RNA-polymerase-based *in vivo* biosensors 43
  - RNA polymerase-mediated PACE 42
  - RNA polymerases like transcription factors 41
  - RNA riboswitches 35, 37
  - RNA-type biosensors 32–35
  - Rosetta 118, 135, 145, 156, 159, 160, 181, 257, 258
  - ruthenium catalyst 186
  - ruthenium photosensitizer 184–186
- S**
- Saccharomyces cerevisiae*
    - advantages 302
    - recombination machinery 302–304
    - signal peptides, evolution of 297–300
  - saturation mutagenesis (SM) 3, 105–124, 154, 161, 164, 197, 211, 212, 214, 215, 217, 221, 230, 268, 269, 271, 273, 275, 277–280, 283–287, 305
  - scaffolding-based surface display system 92
  - SCHEMA-RASSP computational algorithm 305, 306
  - second-generation CAR 362–363
  - secretion mutations, in mature protein 300–301

- selective expression medium (SEM), for  
enzyme production 308
- selenocysteine (Sec) 246, 251
- selenomethionine (SeM) 251
- self-assembled monolayer (SAM) 58, 65
- semisupervised methods 144
- sfCherry11 386, 387
- SH3-domain-containing proteins  
(SH3-CPs) 249
- simvastatin 226, 227
- single-chain bispecific CARs 358
- single chain T cell receptors (scTCRs)  
mutants 84
- single-chain variable fragment (scFvs)  
85, 356, 384
- single codon saturation mutagenesis  
(SCSM) approach 215
- single domain antibodies 318, 319, 321,  
384
- single-probe autosampler 63
- single-site saturation mutagenesis (SSM)  
106, 118, 161, 277
- single-stranded DNA aptamers 35
- sitagliptin 266
- site-directed mutagenesis 121, 124, 170,  
189, 192, 194, 197–200, 246, 271,  
283–285
- site-specific labeling 249
- small split FPs 386
- SNAP-tag 379, 385
- solid-phase chemical synthesis, of SM  
libraries 118–120
- solid-phase peptide synthesis 246
- solifenacin 275, 283
- solvent-exposed lysine residues 319
- somatic hypermutation (SHM) 9,  
18–20, 326, 337
- sortase mediated ligations 168
- split fluorescent proteins 383
- Src-family kinase (SFK) 389
- STAT3 phosphorylation 250
- Staphylococcus aureus* sortase A (SrtA)  
83, 88
- statistical coupling analysis (SCA) 144,  
145
- statistical modeling approach 136, 145
- Staudinger ligation method 246, 254
- stochastic optical reconstruction  
microscopy (STORM) 387
- strain-promoted azide–alkyne  
cycloaddition (SPAAC) 192, 255
- streptavidin-based artificial  
metalloenzymes 198, 199
- styrene derivatives, anti-Markovnikov  
oxidation of 217
- styrene oxidation 187
- sulfite reductase (SiR) 181, 253
- sulfite reduction 181
- sulfotransferases (STs) 154, 164, 166,  
168
- sulopenem 269, 270, 285
- Super Cyan Fluorescent Protein 3A  
(SCFP3A) 381
- superfolder yellow fluorescent protein  
(sfYFP) 255
- super-resolution microscopy 379, 387,  
394
- supervised learning technique 141
- SUPRA CARs 358, 359
- supramolecular anchoring, in native  
protein 187–188
- surface display methods 257
- surface exposed residues 320
- Suzuki–Miyaura cross-coupling 200
- switchable CARs 359
- SynNotch receptors 367–369
- synthetic antibodies 82
- synthetic library derived antibodies  
324–325
- synthetic on-chip Twist method, for SM  
library construction 119
- synthetic receptors 5, 321, 367
- t**
- TaGTEAM 8, 16, 17
- tandem CAR (TanCAR) 357, 358
- target-binding antibodies, screening for  
host-derived antibodies 325
- humanization 327
- immunization 325–326

- pairing variable regions 326–327
  - synthetic library derived antibodies 324–325
  - testosterone, P450-BM3 catalyzed C16-selective hydroxylation of 115
  - TGF- $\beta$ -responsive CAR 360
  - therapeutic antibodies 317
  - therapeutic optimization, of antibodies 328–336
  - Thermoanaerobacter brockii* (TbSADH) 110
  - THIOMAB platform 320
  - third-generation CAR 355, 362–364
  - ticagrelor intermediate 268, 283
  - tissue localization 328, 335
  - Tobacco Etch Virus (TEV) protease 31, 38, 90
  - toll-like receptor 2 (TLR2) 364
  - tonic signaling 355, 363
  - Total Activity Improvements (TAI) 307
  - transaminase ATA-036 activity 66
  - transaminase (TA) 266–267, 286
  - transcription factor-based biosensors 37–39, 41, 44
  - transcription factor-type biosensors
    - advantage 37
    - feedback resistant enzyme development 38
    - 3-hydroxypropionic acid 37
    - ligand-binding units 39
    - phenol-specific 37
  - transferases 64, 266–267
  - transfer hydrogenation
    - imines 195–197
    - ketones 195
    - redox cascades 197
  - transmembrane domain 85, 321, 353, 355, 362
  - trastuzumab therapy 323
  - 1,2,3-trichloropropane (TCP) 280
  - (*R*)-5,5,5-trifluorovaline 271
  - triple code saturation mutagenesis (TCSM) 269
  - alcohol dehydrogenase TbSADH 110–112
  - limonene epoxide hydrolase 109–110
  - mutability landscaping 115–117
  - P450-BM3 catalyst 112–115
  - TriVersa NanoMate system 63
  - T7 RNA polymerase biosensor 42
  - tryptophan biosynthesis 41
  - TtgR transcriptional repressor 31, 39
  - Twist platform 119
  - type I amine oxidases 274
  - type II amine oxidases 274
  - Tyr residue, in heme-copper oxidase (HCO) 251
- U**
- UniProt database 136
  - unnatural amino acid (UAA) 218, 219, 245–258, 272, 278
  - unnatural amino acid incorporation 246–247
    - amino acid replacement 246
    - chemical mutagenesis 246
    - enzyme design 252–255
    - EPR spectroscopy 249
    - flexibility 247
    - fluorescent spectroscopy 250
    - $^{19}\text{F}$  NMR spectra 249
    - genetic code reprogramming 247
    - increasing protein stability 247, 248
    - native chemical ligation method 246
    - nuclear magnetic resonance (NMR) spectroscopy 249
    - solid-phase peptide synthesis 246
    - spectroscopic methods for mechanistic study 248–250
    - Staudinger ligation method 246
    - through genetic code expansion 256
    - tuning catalytic activity 250–252
    - tuning selectivity 252
    - Tyr residue 251, 254
  - unnatural amino acid mutagenesis 218
  - unspecific peroxygenase (UPOs) 162, 295, 296
  - unsupervised learning 144, 144, 145

upper-confidence bound (UCB)  
algorithms 146, 147

**v**

vascular endothelial growth factor  
(VEGF)-responsive MESA 369  
Venus/CFP FRET-based probes 389  
verapamil 225  
versatile peroxidases (VPs) 162, 296  
oxidative stability 303, 304, 307  
thermostability 304, 307  
vibegron 270, 287

**y**

yeast co-display system 91

yeast endoplasmic reticulum  
sequestration screening (YESS)  
technique 90  
yeast functional expression  
codon usage 301–302  
secretion mutations, in mature protein  
300–301  
signal peptides, evolution of 297–300  
yeast glycosylation patterns 334  
yeast prepro-leaders 299  
yeast-surface display (YSD) techniques  
82, 84–85, 89, 385  
yellowameleon-Nano sensor 388

**z**

28z CAR-T cells 363









